LDS/Medical Tests/Testosterone, Bioavailable

Testosterone, Bioavailable

Testosterone is the major androgen (sex hormone) in males. Its production is controlled by luteinizing hormone (LH), which is released from the anterior pituitary gland. Testosterone stimulates adult maturation of external genitalia and secondary sex characteristics such as the growth of beard and body hair. In addition, testosterone has anabolic (process of the growth of bone and muscle) effects leading to increased linear growth, nitrogen retention, and muscular development. Clinical evaluation of serum testosterone, along with serum LH, assists in evaluation of hypogonadal males. Major causes of lowered testosterone in males include hypogonadotropic hypogonadism, testicular failure, hyperprolactinemia, hypopituitarism, some types of liver and kidney diseases, and critical illness.

Testosterone levels are much lower in females compared to males. The major sources of testosterone in females are the ovaries, adrenal glands, and from peripheral conversion of androstenedione. In females, increased serum testosterone levels may be indicative of polycystic ovary syndrome and adrenal hyperplasia. The clinical manifestations of excess testosterone include infertility, hirsutism (excessive hairiness), amenorrhea (lack of menstruation), and obesity;  some experience marked mood swings with aggressive tendencies.

Testosterone strongly binds to plasma proteins. It is largely bound to albumin (38%) and to a specific sex hormone-binding globulin (SHBG) or testosterone-estradiol-binding globulin (TeBG) (60%), but it is the free hormone (1-3%) that is physiologically active. Historically, only the free form of testosterone was thought to be biologically active; however, some testosterone that is nonspecifically and weakly bound to albumin can dissociate freely, becoming available for tissue uptake through the capillary bed. Free and albumin-bound testosterone levels are considered to be bioavailable. Blood testosterone levels depend on rates of production, interconversion, metabolic clearance, and binding protein concentrations. Medication, various disease states, age, and some hormones can alter SHBG levels; therefore, concentrations of free testosterone and bioavailable testosterone more accurately reflect bioactive levels of testosterone than the measurement of total testosterone. For patients with suspected protein abnormalities, such as nephritic syndrome, cirrhosis of the liver, or pregnancy, bioavailable testosterone should be measured rather than free testosterone.

To calculate bioavailable testosterone (depends on the method) free testosterone and SHBG values are needed. Free testosterone can be also calculated from Total testosterone, SHBG, and albumin levels. In addition, free testosterone levels can be obtained by direct testing. Formula for calculation of bioavailable testosterone from direct free testosterone is as follow: Bio Testosterone = Free testosterone X 23.43.

  • Evaluation of LH secretion and Leydig cell function
  • Evaluation of gonadal and adrenal function
  • Diagnosis of hypogonadism in males and hirsutism and virilization in females
  • Infertility (men and women)
  • Testicular tumors
  • Hormone (testosterone) therapy monitoring in postmenopausal women

Increased in:

  • Idiopathic sexual precocity (in boys, levels may be in adult range)
  • Polycystic ovary syndrome (in females)
  • Adrenal hyperplasia
  • Adrenocortical tumors
  • Trophoblastic disease during pregnancy
  • Idiopathic hirsutism
  • Virilizing ovarian tumors
  • Arrhenoblastoma
  • Virilizing luteoma
  • Liver cirrhosis (through increased SHBG)
  • Hyperthyroidism
  • Hyperandrogenism
  • In some drugs such as anticonvulsants, barbiturates, estrogens, oral contraceptives (through increased SHBG)

Decreased in:

  • Hypogonadism
  • Orchidectomy
  • Klinefelter syndrome
  • Liver insufficiency
  • In some drugs: digoxin, spironolactone, acarbose

Note: The diagnosis of male hypogonadism is based on clinical symptoms and signs plus laboratory confirmation of low morning total serum testosterone levels on two different occasions. Levels below 3.0 ng/mL should be treated. Free testosterone should be measured in symptomatic patients with normal total testosterone levels. Obtain serum luteinizing hormone and FSH levels to distinguish between primary (hypergonadotropic) and secondary (hypogonadotropic) hypogonadism. Hypogonadism associated with aging (andropause) may present a mixed picture, with low testosterone levels and low to low-normal gonadotropin levels.

Group ng/dL nmol/L
Adult Male 66–417 2.29–14.5
Adult Female 0.6–5.0 0.02–0.129
                                                                   % of Total                                 Fraction of Total
Adult Male 12.3–63.0% 0.123–0.630
Adult Female 2.4–12.9% 0.024–0.129
Chemiluminescent enzymeimmunoassay, Liquid chromatography and Mass spectrometry (LC/MS).

Serum (SST). 

Stability

  • Ambient: 5-7 days
  • Refrigerated: 7-14 days
  • Frozen: 4 months
Luteinizing hormone (LH), Follicle-stimulating hormone (FSH), estrogen, testosterone free, sex hormone-binding globulin (SHBG), Aldosterone, Vitamin D-25OH, Cortisol, Dihydroepiandrosterone, Dihydrotestosterone, Inhibin A, Calcium, Complete Semen Analysis.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Ann Clin Biochem. 2006 Jan;43(Pt 1):3-12. [PMID: 16390603]
  • Front Horm Res. 2009;37:21-31. [PMID: 19011286]
  • Methods Mol Biol. 2006;324:197-211. [PMID: 16761380]
  • Ann Clin Biochem. 1995 Jul;32 ( Pt 4):345-57. [PMID: 7486793]
  • Best Pract Res Clin Endocrinol Metab. 2006;20:177. [PMID: 16772150]
  • Testosterone. In Mosby's Dictionary of Medicine, Nursing and Health Professions, 8th Edition (p. 654). St. Louis: Mosby Elsevier (2009).
  • Diagnostics Biochem Canada Inc. package insert Free Testosterone Version 3.1, September 2007
  • Burtis C, Ashwood E, and Bruns D. Fundamentals of Clinical Chemistry. St. Louis: Saunders (2008).
  • Sandhya Pruthi M. (2008, July 20). Menopause. Retrieved July 10, 2010, from Mayo Clinic.com: http://www.mayoclinic.com/health/testosterone-therapy/AN01390